turbutaline.txt

Brethine

Sympathomimetic bronchodilator

• Selective beta-2 adrenergic receptor activity resulting in relaxation of smooth muscles of the bronchial tree and peripheral vasculature.
• Minimal cardiac effects.

• Bronchial asthma
• Reversible bronchospasm associated with exercise, chronic bronchitis, and emphysema.

• Hypersensitivity.
• Tachydysrhythmias

Usually transient and dose-related, restlessness, apprehension, palpitations, tachycardia chest pain, coughing, bronchospasm, nausea, facial flushing

• Cardiovascular effects exacerbated by other sympathomimetics
• MAOIs may potentiate dysrhythmias
• Beta blockers may antagonize terbutaline

• MDI: 200 mcg/metered spray.
• Parenteral: 1 mg/ml ampule

• 0.25 mg SC; may repeat in 15-30 minutes to maximum dose of 0.5 mg in 4 hours period.
• 400 mcg (two inhalations by MDI) every 4-6 hours; allow 1-2 minutes between inhalations

• Not recommended for children under 12 years of age.
• 0.01 mg / kg / dose SC every 15-20 minutes PRN to maximum 0.25 mg dose.
• 0.03 -0.05 mg / kg in 1.25 ml saline for aerosolization every 4 hours

• Onset: SC: 15-30 minutes; MDI 5-30 minutes
• Peak effect: Variable
• Duration: SC: 1.5-4 hours; MDI: 3-6 hours

• Pregnancy safety:Category B
• Carefully monitor vital signs
• Use with caution in patients with cardiovascular disease or hypertension
• Patient should receive oxygen before and during bronchodilator administration